3/4
12:34 am
sprb
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway [Yahoo! Finance]
Medium
Report
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway [Yahoo! Finance]
3/2
04:35 pm
sprb
Spruce Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
Spruce Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
3/2
04:05 pm
sprb
Spruce Biosciences to Present at Upcoming Investor Conferences in March
Low
Report
Spruce Biosciences to Present at Upcoming Investor Conferences in March
2/19
07:07 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/18
07:00 am
sprb
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Medium
Report
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
2/17
04:28 pm
sprb
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
04:05 pm
sprb
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/5
04:05 pm
sprb
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Low
Report
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
2/3
08:36 am
sprb
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
Medium
Report
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
2/3
08:00 am
sprb
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Medium
Report
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
1/28
08:00 am
sprb
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
Medium
Report
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
1/19
01:53 am
sprb
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]
Medium
Report
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]
1/18
07:02 pm
sprb
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Medium
Report
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
1/8
08:00 am
sprb
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Medium
Report
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
12/27
01:05 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre
12/23
07:17 am
sprb
Spruce Biosciences (NASDAQ:SPRB) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
12/22
08:02 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.
High
Report
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.
12/15
08:20 am
sprb
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]
Medium
Report
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]
12/15
08:00 am
sprb
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Medium
Report
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
12/6
01:36 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street